Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Combination of Gefitinib With Chemotherapy or Anti-angiogenesis as 1st Line Treatment in Advanced NSCLC Patients Detected With Bim Deletion or Low EGFR Activating Mutation Abundance

NCT02930954 is registered in ClinicalTrials.gov with Caicun Zhou as lead sponsor.

NCT NCT02930954
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02930954 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Combination of Gefitinib With Chemotherapy or Anti-angiogenesis as 1st Line Treatment in Advanced NSCLC Patients Detected With Bim Deletion or Low EGFR Activating Mutation Abundance
Lead sponsor
Caicun Zhou
Phase
Phase 2
Overall status
Unknown status
Start date
November 30, 2016
Completion date
December 31, 2018
Enrollment
180 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

non-small-cell lung cancer